ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

23 12月 2021 08:00:00 条件 Nasdaq GlobeNewswire

FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

22 12月 2021 16:01:00 条件 Nasdaq GlobeNewswire

Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

16 12月 2021 08:00:01 条件 Nasdaq GlobeNewswire

Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream

13 12月 2021 08:00:01 条件 Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

10 11月 2021 08:02:00 条件 Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

04 11月 2021 16:02:00 条件 Nasdaq GlobeNewswire

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

04 10月 2021 08:00:01 条件 Nasdaq GlobeNewswire

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

30 9月 2021 08:30:00 条件 Nasdaq GlobeNewswire

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

28 9月 2021 16:05:00 条件 Nasdaq GlobeNewswire

New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress

27 9月 2021 08:05:00 条件 Nasdaq GlobeNewswire